



**Celadon Pharmaceuticals Plc**

("Celadon", the "Company" or the "Group")

**Update on CFO Appointment**

**London, 13 January 2023** - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, is pleased to announce that further to the RNS of 1 November 2022 Jonathan Turner will formally join the Company and be appointed to the Board as Chief Financial Officer on 17 January 2023.

**Enquiries:**

**Celadon Pharmaceuticals Plc**

James Short  
Arthur Wakeley

Via Powerscourt

**Canaccord Genuity Limited (Nominated Adviser and Broker)**

Bobbie Hilliam / Andrew Potts / Patrick Dolaghan

+44 (0)20 7523 8000

**Powerscourt Group**

Sarah MacLeod / Nick Johnson / Sam Austrums /  
Ibrahim Khalil

+44 (0)20 7250 1446

**About Celadon Pharmaceuticals Plc**

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office Licence to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website [www.celadonpharma.co.uk](http://www.celadonpharma.co.uk)

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FURFLFEDLSIFLIV